100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
Previously searched by you
NR 503 Epidemiology Final Exam ( Version 1) / NR503 Final Exam: Population Health, Epidemiology & Statistical Principles: Chamberlain College Of Nursing | 100 % VERIFIED ANSWERS, GRADE A$20.49
Add to cart
NR 503 Epidemiology Final Exam ( Version 1) / NR503 Final Exam: Population Health, Epidemiology & Statistical Principles: Chamberlain College Of Nursing | 100 % VERIFIED ANSWERS, GRADE A
NR 503 Epidemiology Final Exam / NR503 Epidemiology Final Exam: Population Health, Epidemiology & Statistical Principles: Chamberlain College Of Nursing
Chamberlain NR 503 Epidemiology Final Exam / Chamberlain NR503 Final Exam: Population Health, Epidemiology & Statistical Principles
Question 1
A ...
nr 503 epidemiology final exam nr503 epidemiology final exam population health
epidemiology statistical principles chamberlain college of nursing chamberlain nr 503 epidemiology final exam ch
Written for
CHAMBERLAIN COLLEGE OF NURSING
NR503 (NR503)
All documents for this subject (65)
6
reviews
By: jdubwolfinger • 1 year ago
By: livancitovaldes9 • 2 year ago
By: dabulge • 2 year ago
By: trosnuk • 3 year ago
there is not even one question or answer that was related to the final exam
By: stephenarrey • 4 year ago
How can I get my refund
By: rdohnalek • 4 year ago
Seller
Follow
chamberlain_university
Reviews received
Content preview
NR 503 Final Exam
Question
A randomized, double-blind clinical trial of a varicella vaccine observed an estimated incidence
of 25% chickenpox episodes in persons receiving the vaccine, compared to 80% among persons
receiving a placebo. The estimated efficacy of the vaccine is:
55.0%
65.0%
68.8%
71.4%
80.0%
Explanation
The efficacy is calculated by subtracting the rate in those vaccinated from the placebo rate and
dividing by the placebo rate. In this example, 80% minus 25% equals 55%. Dividing by 80%
results in an efficacy of 68.8%.
Question
A study is conducted for a pharmaceutical agent that has shown promise for reducing heart
disease among women. In order to more fully test the agent, an additional study is done
restricting the participants to be randomized to those who have a history of hypertension. Which
of the following advantages cannot be claimed by the researchers?
Power of the study is increased
Potential benefits in high-risk populations are increased
Validity of the study is increased by focus on a homogenous population
The generalizability of the study is increased
The overall cost of the study is decreased
Explanation
Restricting the study to a high-risk group will only fail to increase the generalizability of the
findings since the study results will apply only to a more specific group of women who share a
history of hypertension.
Question
, A new drug treatment for cardiac thrombus claims to have a higher success rate than the current
drug. A strong sign of the potential success is the lack of internal hemorrhaging starting 2 days
after treatment. 168 patients who require treatment for cardiac thrombi are randomized after
agreeing to participate in a trial of the new drug. The researchers were interested in whether the
new drug reduced the need for blood transfusions due to internal hemorrhage compared to the
current treatment. The following table summarizes the results of her study:
What is the incidence of needing a blood transfusion in the group of persons who were
randomized to the new drug treatment?
31.0%
41.1%
51.2%
62.3%
Incidence cannot be calculated with the information in this table
Explanation
Incidence is the development of the outcome under investigation among those at risk. In this
instance, 43 participants “developed” the need for a blood transfusion among the 84 persons in
the new drug treatment group.
Question
A new drug treatment for cardiac thrombus claims to have a higher success rate than the current
drug. A strong sign of the potential success is the lack of internal hemorrhaging starting 2 days
after treatment. 168 patients who require treatment for cardiac thrombi are randomized after
agreeing to participate in a trial of the new drug. The researchers were interested in whether the
new drug reduced the need for blood transfusions due to internal hemorrhage compared to the
current treatment. The following table summarizes the results of her study:
What is the number of persons who died in hospital in the study?
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller chamberlain_university. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $20.49. You're not tied to anything after your purchase.
